Literature DB >> 27175025

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.

Koji Sasaki1, Hagop Kantarjian2, Elias Jabbour2, Farhad Ravandi2, Koichi Takahashi2, Marina Konopleva2, Gautam Borthakur2, Guillermo Garcia-Manero2, William Wierda2, Naval Daver2, Preetesh Jain2, Toshihisa Satta2, Sherry Pierce2, May Beth Rios2, Jorge E Cortes3.   

Abstract

Entities:  

Keywords:  chronic myeloid leukemia; dasatinib; high-dose imatinib; nilotinib

Mesh：

Substances：

Year:  2016        PMID： 27175025      PMCID： PMC4967581          DOI： 10.3324/haematol.2015.139089

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Authors:  Michael W Deininger; Kenneth J Kopecky; Jerald P Radich; Suzanne Kamel-Reid; Wendy Stock; Elisabeth Paietta; Peter D Emanuel; Martin Tallman; Martha Wadleigh; Richard A Larson; Jeffrey H Lipton; Marilyn L Slovak; Frederick R Appelbaum; Brian J Druker
Journal:  Br J Haematol       Date:  2013-11-04       Impact factor: 6.998

2.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

3.  Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor.

Authors:  Jorge Cortes; Alfonso Quintás-Cardama; Dan Jones; Farhad Ravandi; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Jody Hiteshew; Jenny Shan; Susan O'Brien; Hagop Kantarjian
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

4.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Authors:  Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Authors:  Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Charles Koller; Gautam Borthakur; Brenda Walker; Weiqiang Zhao; Jianqin Shan; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.

Authors:  Preetesh Jain; Hagop Kantarjian; Mona Lisa Alattar; Elias Jabbour; Koji Sasaki; Graciela Nogueras Gonzalez; Sara Dellasala; Sherry Pierce; Srdan Verstovsek; William Wierda; Gautam Borthakur; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Lancet Haematol       Date:  2015-03-20       Impact factor: 18.959

7.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies.

Authors:  Peter C Austin
Journal:  Pharm Stat       Date:  2011 Mar-Apr       Impact factor: 1.894

8.  Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials.

Authors:  Koji Sasaki; Sara S Strom; Susan O'Brien; Elias Jabbour; Farhad Ravandi; Marina Konopleva; Gautam Borthakur; Naveen Pemmaraju; Naval Daver; Preetesh Jain; Sherry Pierce; Hagop Kantarjian; Jorge E Cortes
Journal:  Lancet Haematol       Date:  2015-04-20       Impact factor: 18.959

9.  Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Authors:  Jorge E Cortes; Dan Jones; Susan O'Brien; Elias Jabbour; Marina Konopleva; Alessandra Ferrajoli; Tapan Kadia; Gautam Borthakur; Denise Stigliano; Jianqin Shan; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
  10 in total
  3 in total

1.  Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.

Authors:  Mohamed A Ismail; Muthanna Samara; Ali Al Sayab; Mohamed Alsharshani; Mohamed A Yassin; Govindarajulu Varadharaj; Marzia Vezzalini; Luisa Tomasello; Maria Monne; Hisham Morsi; M Walid Qoronfleh; Hatem Zayed; Richard Cook; Claudio Sorio; Helmout Modjtahedi; Nader I Al-Dewik
Journal:  Mol Genet Genomic Med       Date:  2020-07-23       Impact factor: 2.183

2.  A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.

Authors:  José Luis Marín-Rubio; Rachel E Peltier-Heap; Maria Emilia Dueñas; Tiaan Heunis; Abeer Dannoura; Joseph Inns; Jonathan Scott; A John Simpson; Helen J Blair; Olaf Heidenreich; James M Allan; Jessica E Watt; Mathew P Martin; Barbara Saxty; Matthias Trost
Journal:  J Med Chem       Date:  2022-09-12       Impact factor: 8.039

3.  First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysis.

Authors:  Kang-Kang Chen; Tai-Feng Du; Ku-Sheng Wu; Wei Yang
Journal:  Cancer Manag Res       Date:  2018-09-25       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.